<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  Imaging Flow Cytometer for High-Throughput High-Content Screening</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>01/01/2015</AwardEffectiveDate>
<AwardExpirationDate>06/30/2015</AwardExpirationDate>
<AwardTotalIntnAmount>149997.00</AwardTotalIntnAmount>
<AwardAmount>149997</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Ruth Shuman</SignBlockName>
<PO_EMAI>rshuman@nsf.gov</PO_EMAI>
<PO_PHON>7032922160</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to improve the efficiency of discovering new drugs by introducing a new type of instrument for fluorescent imaging of cells at high throughput. This innovation will allow pharmaceutical researchers to image individual cells at speeds more than an order of magnitude faster than the state-of-the-art instrumentation, which will improve the rate at which scientists run drug screening experiments. By taking high-resolution images of individual cells during these screening experiments, far more detailed information can be gleaned than using conventional high throughput methods, leading to a deeper scientific understanding of drug-cell interactions. This instrument will address the growing $15 billion drug discovery instrumentation market by providing a new type of high throughput readout capability for the drug discovery industry. Further, the ability to perform multiplexed multi-color fluorescent imaging of cells will reduce the number of experiments required to identify new pharmaceutical compounds, thereby improving the efficiency and reducing the cost of drug discovery, ultimately reducing the time-to-market of new drugs.&lt;br/&gt; &lt;br/&gt;This SBIR Phase I project proposes to develop an imaging flow cytometer instrument to improve the speed of single-cell analysis in the field of drug discovery. While multi-parameter single-cell phenotypic analysis provides great information about the cellular interactions of a pharmaceutical compound, this type of experimental readout is too slow to perform on the large numbers of samples common in a drug discovery laboratory. By performing parallel fluorescent image analysis of cells in flow, this process can be accelerated such that more than 100,000 compounds can be screened each day in an automated laboratory setting. This project aims to develop an instrument capable of such high throughput image analysis using fluorescence, combining techniques and technologies adapted from the fields of flow cytometry and high-speed fluorescence microscopy to accomplish this throughput goal. The successful outcome of this project will yield an instrument capable of imaging cells flowing at meter per second flow rates with diffraction-limited spatial resolution using multiple fluorescent colors.</AbstractNarration>
<MinAmdLetterDate>12/11/2014</MinAmdLetterDate>
<MaxAmdLetterDate>12/11/2014</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>0</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1447381</AwardID>
<Investigator>
<FirstName>Eric</FirstName>
<LastName>Diebold</LastName>
<PI_MID_INIT>D</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Eric D Diebold</PI_FULL_NAME>
<EmailAddress>diebold.e@gmail.com</EmailAddress>
<PI_PHON>4014390159</PI_PHON>
<NSF_ID>000669881</NSF_ID>
<StartDate>12/11/2014</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Omega Biosystems Incorporated</Name>
<CityName>Los Angeles</CityName>
<ZipCode>900644514</ZipCode>
<PhoneNumber>4014390159</PhoneNumber>
<StreetAddress>10316 Bannockburn Dr</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<StateCode>CA</StateCode>
<CONGRESSDISTRICT>37</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CA37</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>079309785</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>OMEGA BIOSYSTEMS INCORPORATED</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Omega Biosystems Incorporated]]></Name>
<CityName>Los Angeles</CityName>
<StateCode>CA</StateCode>
<ZipCode>900644514</ZipCode>
<StreetAddress><![CDATA[10316 Bannockburn Dr]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>37</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>CA37</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>5371</Code>
<Text>SMALL BUSINESS PHASE I</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<Appropriation>
<Code>0115</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2015~149997</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p class="edbody"><strong>Intellectual Merits:</strong></p> <p class="edbody">This Small Business Innovation Research Phase I project will improve the efficiency of discovering new drugs by the pharmaceutical industry by introducing a phenotypic screening instrument based on high throughput imaging flow cytometry. Phenotypic screening investigates the pharmacological effects and the mechanisms of action of therapeutic compounds by measuring multiple parameters from individual cells in an assay format. This approach differs from target-based screening, in that phenotypic screening does not rely on <em>a priori</em> knowledge of the disease target. This highly effective approach to drug discovery has significant throughput limitations &ndash; namely, it requires data to be collected at the single cell level versus the population level. Low throughput, high-resolution readout techniques, such as flow cytometry or fluorescence imaging, must be used in order to collect such data. In this Phase I SBIR project, we developed the core optical module of a prototype imaging flow cytometer, in order to alleviate the speed limitations associated with flow cytometry and high content imaging in drug discovery. An imaging flow cytometer based on this optical technology will ultimately be capable of performing image acquisition at the sample throughput speeds of traditional high throughput screening. The innovation in this project is centered on an optical technology inspired by orthogonal frequency division multiplexing techniques used in wireless communications, which enables a single element photodetector to function as a high speed imaging detector. This project resulted in a prototype optical system capable of multi-color fluorescence imaging cells in flow at speeds &gt;1 meter per second, with approximately 1 micron spatial resolution. Integrating this technology with conventional fluidic and signal processing architectures in Phase II will result in a high content screening instrument capable of processing 100,000 wells per day in an automated setting, and also capable of producing fluorescence images of cells at a throughput 10x greater than the state-of-the-art imaging flow cytometer.<strong>&nbsp;</strong></p> <p class="edbody"><strong>Broader Impacts:</strong></p> <p class="edbody">Currently, no high-throughput imaging flow cytometer exists to satisfy the market&rsquo;s demand for high throughput, high content data. The lack of throughput in high content readers is a pain point of the drug discovery industry. The introduction of such a high throughput instrument addresses the multi-billion dollar, rapidly growing flow cytometry and drug discovery instrumentation markets. The proposed solution, which combines flow cytometry and high content imaging offers several distinct order-of-magnitude performance advantages versus other cell analysis technologies, which will ultimately yield an increase in the efficiency of drug discovery using phenotypic screening. This solution is ideal for our customer base of pharmaceutical companies, contract research organizations, biotechnology companies, flow cytometry core facilities, and academic research laboratories, all of which demand higher throughput in flow cytometry. Outside of drug discovery, the addition of an imaging capability to a high throughput flow cytometer will also enable researchers to perform experiments on other topics such as rare cell detection, further widening our understanding of biomedicine. Finally, a flow cytometer capable of analyzing samples at high throughput will dramatically reduce the time researchers require to perform experiments in already overbooked flow cytometry core facilities, ultimately enabling a general increase in scientific research productivity.</p><br> <p>            Last Modified: 07/10/2015<br>      Modified by: Eric&nbsp;D&nbsp;Diebold</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[Intellectual Merits: This Small Business Innovation Research Phase I project will improve the efficiency of discovering new drugs by the pharmaceutical industry by introducing a phenotypic screening instrument based on high throughput imaging flow cytometry. Phenotypic screening investigates the pharmacological effects and the mechanisms of action of therapeutic compounds by measuring multiple parameters from individual cells in an assay format. This approach differs from target-based screening, in that phenotypic screening does not rely on a priori knowledge of the disease target. This highly effective approach to drug discovery has significant throughput limitations &ndash; namely, it requires data to be collected at the single cell level versus the population level. Low throughput, high-resolution readout techniques, such as flow cytometry or fluorescence imaging, must be used in order to collect such data. In this Phase I SBIR project, we developed the core optical module of a prototype imaging flow cytometer, in order to alleviate the speed limitations associated with flow cytometry and high content imaging in drug discovery. An imaging flow cytometer based on this optical technology will ultimately be capable of performing image acquisition at the sample throughput speeds of traditional high throughput screening. The innovation in this project is centered on an optical technology inspired by orthogonal frequency division multiplexing techniques used in wireless communications, which enables a single element photodetector to function as a high speed imaging detector. This project resulted in a prototype optical system capable of multi-color fluorescence imaging cells in flow at speeds &gt;1 meter per second, with approximately 1 micron spatial resolution. Integrating this technology with conventional fluidic and signal processing architectures in Phase II will result in a high content screening instrument capable of processing 100,000 wells per day in an automated setting, and also capable of producing fluorescence images of cells at a throughput 10x greater than the state-of-the-art imaging flow cytometer.  Broader Impacts: Currently, no high-throughput imaging flow cytometer exists to satisfy the marketÃ†s demand for high throughput, high content data. The lack of throughput in high content readers is a pain point of the drug discovery industry. The introduction of such a high throughput instrument addresses the multi-billion dollar, rapidly growing flow cytometry and drug discovery instrumentation markets. The proposed solution, which combines flow cytometry and high content imaging offers several distinct order-of-magnitude performance advantages versus other cell analysis technologies, which will ultimately yield an increase in the efficiency of drug discovery using phenotypic screening. This solution is ideal for our customer base of pharmaceutical companies, contract research organizations, biotechnology companies, flow cytometry core facilities, and academic research laboratories, all of which demand higher throughput in flow cytometry. Outside of drug discovery, the addition of an imaging capability to a high throughput flow cytometer will also enable researchers to perform experiments on other topics such as rare cell detection, further widening our understanding of biomedicine. Finally, a flow cytometer capable of analyzing samples at high throughput will dramatically reduce the time researchers require to perform experiments in already overbooked flow cytometry core facilities, ultimately enabling a general increase in scientific research productivity.       Last Modified: 07/10/2015       Submitted by: Eric D Diebold]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
